中文

智飞生物 Revenue Breakdown

Period 2026-06-30 ・ Reported 2026-08-29

智飞生物 reported revenue of ¥4.02B for the period ended 2026-06-30, -18.4% year on year. Net income was ¥-0.82B, a -20.4% net margin on a 18.1% gross margin. The largest revenue line is 代理产品 at 89% of the total. Free cash flow for the period was ¥1.60B.

ItemAmountY/Y
Revenue¥4.02B-18.4%
Gross profit¥0.73B
Operating income¥-0.97B
Net income¥-0.82B
Gross margin18.1%Net margin -20.4%
Revenue Q/Q-12.9%

Revenue Segments

SegmentRevenueShare
代理产品¥3.59B89.3%
自主产品¥0.38B9.5%
其他¥0.05B1.2%

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥3.30B81.9%
R&D¥0.43B10.6%
SG&A¥0.93B23.1%
Tax & other¥-0.15B-3.7%

Balance sheet & cash flow

ItemAmount
Total assets¥27.82B
Total liabilities¥12.53B
Shareholders' equity¥15.29B
Equity / assets54.9%
Operating cash flow¥1.70B
Capital expenditure¥0.10B
Free cash flow¥1.60B
Cash conversion (OCF / net income)-241%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

汇川技术光线传媒阳光电源中际旭创晶盛机电天孚通信三环集团芒果超媒昆仑万维蓝思科技润泽科技先导智能

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies